000276341 001__ 276341
000276341 005__ 20250216000753.0
000276341 0247_ $$2doi$$a10.1016/j.exger.2025.112684
000276341 0247_ $$2pmid$$apmid:39824235
000276341 0247_ $$2ISSN$$a0531-5565
000276341 0247_ $$2ISSN$$a1873-6815
000276341 0247_ $$2altmetric$$aaltmetric:173429399
000276341 037__ $$aDZNE-2025-00289
000276341 041__ $$aEnglish
000276341 082__ $$a610
000276341 1001_ $$aLohner, Valerie$$b0
000276341 245__ $$aAssociations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome.
000276341 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000276341 3367_ $$2DRIVER$$aarticle
000276341 3367_ $$2DataCite$$aOutput Types/Journal article
000276341 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739354471_25680
000276341 3367_ $$2BibTeX$$aARTICLE
000276341 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276341 3367_ $$00$$2EndNote$$aJournal Article
000276341 520__ $$aIn light of growing evidence highlighting interactions between cardiac and brain health, we investigated associations of biomarkers of neurodegenerative diseases with adverse outcomes (all-cause and cardiovascular mortality, major cardiovascular events, and stroke) in persons with chronic coronary syndrome (CCS).We used data from a cohort of persons with CCS for whom major adverse events were recorded over a follow-up of 20 years. We measured biomarkers of neurodegenerative diseases in baseline blood samples, using the Single-Molecule Array Technology on a HD-1 Analyzer. These include biomarkers of neuronal (neurofilament light chain (NfL) (n = 379)) and glial neurodegeneration (glial fibrillary acidic protein (GFAP) (n = 379)), and Alzheimer's disease pathology (phosphorylated tau181 (n = 379), total tau (n = 377), and amyloid β (Aβ40, Aβ42, Aβ42/Aβ40) (n = 377)). We applied Cox-proportional hazards models to evaluate associations of these biomarkers with adverse outcomes, adjusting for covariates and exploring interactions with apolipoprotein E (ApoE) ε4 genotype.Participants with higher NfL levels had increased rates of all-cause and cardiovascular mortality (Hazard ratio per increase by one standard deviation (95 % confidence interval): all-cause mortality: 1.36 (1.10-1.68); cardiovascular mortality: 1.42 (1.05-1.93)). The Aβ40/Aβ42-ratio was linked to incident stroke (0.72 (0.52-1.00)). Associations of GFAP with all-cause mortality and incident stroke were depending on ApoE ε4 genotype. The other biomarkers were not significantly associated with the studied outcomes.In persons with CSS, NfL and the Aβ40/Aβ42-ratio were related to mortality and incident stroke, respectively, whereas associations of GFAP with adverse outcomes varied by ApoE genotype. These biomarkers might play a role in linking aging, cardiovascular and neurodegenerative diseases.
000276341 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276341 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276341 650_7 $$2Other$$aBlood-based biomarkers of neurodegenerative diseases
000276341 650_7 $$2Other$$aCerebrovascular events
000276341 650_7 $$2Other$$aChronic coronary syndrome
000276341 650_7 $$2Other$$aCoronary heart disease
000276341 650_7 $$2Other$$aEpidemiology
000276341 650_7 $$2Other$$aMajor cardiovascular events
000276341 650_7 $$2Other$$aMortality
000276341 650_7 $$2NLM Chemicals$$aBiomarkers
000276341 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000276341 650_7 $$2NLM Chemicals$$atau Proteins
000276341 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000276341 650_7 $$2NLM Chemicals$$aneurofilament protein L
000276341 650_7 $$2NLM Chemicals$$aGFAP protein, human
000276341 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000276341 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000276341 650_2 $$2MeSH$$aHumans
000276341 650_2 $$2MeSH$$aBiomarkers: blood
000276341 650_2 $$2MeSH$$aFemale
000276341 650_2 $$2MeSH$$aMale
000276341 650_2 $$2MeSH$$aAged
000276341 650_2 $$2MeSH$$aMiddle Aged
000276341 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000276341 650_2 $$2MeSH$$aNeurodegenerative Diseases: blood
000276341 650_2 $$2MeSH$$aNeurodegenerative Diseases: mortality
000276341 650_2 $$2MeSH$$atau Proteins: blood
000276341 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000276341 650_2 $$2MeSH$$aStroke: blood
000276341 650_2 $$2MeSH$$aStroke: mortality
000276341 650_2 $$2MeSH$$aCardiovascular Diseases: mortality
000276341 650_2 $$2MeSH$$aCardiovascular Diseases: blood
000276341 650_2 $$2MeSH$$aProportional Hazards Models
000276341 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000276341 650_2 $$2MeSH$$aNeurofilament Proteins
000276341 7001_ $$aPerna, Laura$$b1
000276341 7001_ $$aSchöttker, Ben$$b2
000276341 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b3$$udzne
000276341 7001_ $$aBrenner, Hermann$$b4
000276341 7001_ $$aMons, Ute$$b5
000276341 773__ $$0PERI:(DE-600)2005397-6$$a10.1016/j.exger.2025.112684$$gVol. 200, p. 112684 -$$p112684$$tExperimental gerontology$$v200$$x0531-5565$$y2025
000276341 8564_ $$uhttps://pub.dzne.de/record/276341/files/DZNE-2025-00289%20SUP.pdf
000276341 8564_ $$uhttps://pub.dzne.de/record/276341/files/DZNE-2025-00289.pdf$$yOpenAccess
000276341 8564_ $$uhttps://pub.dzne.de/record/276341/files/DZNE-2025-00289%20SUP.pdf?subformat=pdfa$$xpdfa
000276341 8564_ $$uhttps://pub.dzne.de/record/276341/files/DZNE-2025-00289.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276341 909CO $$ooai:pub.dzne.de:276341$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276341 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000276341 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276341 9141_ $$y2025
000276341 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000276341 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000276341 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-13T12:49:31Z
000276341 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-13T12:49:31Z
000276341 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276341 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000276341 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-02$$wger
000276341 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000276341 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000276341 980__ $$ajournal
000276341 980__ $$aVDB
000276341 980__ $$aUNRESTRICTED
000276341 980__ $$aI:(DE-2719)5000022
000276341 9801_ $$aFullTexts